News
CVS Caremark to Place Wegovy as Preferred GLP-1 for Weight Loss
Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies. Effective July 1, 2025, CVS Caremark will place Novo Nordisk’s Wegovy (semaglutide) injection 2.4 mg on its largest commercial template formularies as the preferred GLP-1 medication for patients with obesity.
A new study found users of one drug lost almost 50 percent more weight that users of Wegovy. People taking Eli Lilly’s ...
Allison Stange lost 40 pounds since starting Zepbound in April 2024, improving both her blood pressure and sleep apnea. Now ...
In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of ...
The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...
Approximately 9,000 CVS locations will begin selling Wegovy for $499 per month to customers who pay cash out of pocket.
Shares of CVS Health Corp. CVS soared toward a one-year ... Obamacare business and will increase access to weight-loss drug Wegovy as it reported blowout earnings. The company said it decided ...
A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.Despite last ...
Obesity drugmaker Novo Nordisk cut its sales forecasts on Wednesday for the first time since the launch of its Wegovy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback